Abstract
In the last years we have learned a lot about the pathopysiology of a cluster of the diseases called Metabolic Syndrome but currently an exciting discussion debates the Metabolic Syndrome in a light of a mystery of medicine or a clinical paradigm with a controversary about diagnostic, treatment or preventive procedure. There is now convincing evidence that prevention is the most important and effective way to reduce the personal and socio-economic burden of the Metabolic Syndrome and its associated complications. Still, it is currently not clear how to implement preventive interventions into clinical practice but will require an integrated and transdisciplinary approach on an international level in order to efficiently reduce premature morbidity and mortality. Nevertheless, global strategies are still lacking but are needed to tackle inequalities in health between industrialized countries and the developing world. A global health strategy has to take into account political, epidemiological, environmental, infrastructural and genetic aspects. The Metabolic Syndrome is not a mystery - it is a clinical paradigm and global challenge.
Key words
metabolic syndrome - global health - prevention - type 2 diabetes - intervention
References
1
Bornstein SR, Wong ML, Licinio J.
150 years of Sigmund Freud: What would Freud have said about the obesity epidemic?.
Mol Psychiatry.
2006;
11
1070-1072
2
Hanefeld M, Ceriello A, Schwarz PE, Bornstein SR.
The metabolic syndrome-a postprandial disease?.
Horm Metab Res.
2006;
38
435-436
3
Schwarz PE, Schwarz J, Bornstein SR, Schulze J.
Diabetes prevention-from physiology to implementation.
Horm Metab Res.
2006;
38
460-464
4
Korenblum W, Barthel A, Licinio J, Wong ML, Wolf OT, Kirschbaum C, Bornstein SR.
Elevated cortisol levels and increased rates of diabetes and mood symptoms in Soviet Union-born Jewish immigrants to Germany.
Mol Psychiatry.
2005;
10
974-975
5
Schwarz PE, Bornstein SR.
Pre-diabetes and metabolic syndrome in Germans.
Horm Metab Res.
2006;
38
359
6
Valensi P, Schwarz EH, Hall M, Felton AM, Maldonato A, Mathieu C.
Pre-diabetes essential action: a European perspective.
Diabetes Metab.
2005;
31
606-620
7
Schwarz PE.
Report from the Congress of the American Diabetes Association (ADA): Orlando 2005 - 65th Annual Scientific Sessions in San Diego, CA, USA, June 10-14th 2005.
Exp Clin Endocrinol Diabetes.
2005;
113
475-479
8
Schwarz PE.
Congress report from the American Diabetes Association 66th Annual Scientific Sessions in Washington, USA.
Exp Clin Endocrinol Diabetes.
2006;
114
605-610
9
Hanefeld M.
LW. Das Metabolische Syndrom.
Dtsch Gesundh Wesen.
1981;
36
545-551
10
Reaven GM.
Banting lecture 1988. Role of insulin resistance in human disease.
Diabetes.
1988;
37
1595-1607
11 World Health Organization .Definition, diagnosis and classification of diabetes mellitus and its complications . Report of a WHO Consultation 1999
12
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).
JAMA.
2001;
285
2486-2497
13
Alberti KG, Zimmet P, Shaw J.
International Diabetes Federation: a consensus on Type 2 diabetes prevention.
Diabet Med.
2007;
24
451-463
14
Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J.
The metabolic syndrome: a global public health problem and a new definition.
J Atheroscler Thromb.
2005;
12
295-300
15
Rudofsky
Jr
G, Reismann P, Schiekofer S, Petrov D, Eynatten M, Humpert PM, Isermann B, Muller-Hoff C, Thai TP, Lichtenstein S, Bartsch U, Hamann A, Nawroth P, Bierhaus A.
Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappaB activation in PBMCs.
Horm Metab Res.
2004;
36
630-638
16
Haslbeck KM, Schleicher E, Bierhaus A, Nawroth P, Haslbeck M, Neundorfer B, Heuss D.
The AGE/RAGE/NF-(kappa)B pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT).
Exp Clin Endocrinol Diabetes.
2005;
113
288-291
17
Schiekofer S, Franke S, Andrassy M, Chen J, Rudofsky G, Schneider JG, Eynatten M von, Wendt T, Morcos M, Kientsch-Engel R, Stein G, Schleicher E, Nawroth PP, Bierhaus A.
Postprandial mononuclear NF-kappaB activation is independent of the AGE-content of a single meal.
Exp Clin Endocrinol Diabetes.
2006;
114
160-167
18
Kamari Y, Grossman E, Oron-Herman M, Peleg E, Shabtay Z, Shamiss A, Sharabi Y.
Metabolic stress with a high carbohydrate diet increases adiponectin levels.
Horm Metab Res.
2007;
39
384-388
19
Kyrou I, Tsigos C.
Stress mechanisms and metabolic complications.
Horm Metab Res.
2007;
39
430-438
20
Schuppenies A, Schwarz P, Bornstein SR.
Seasonal affective disorder and HPA axis disturbance.
Horm Metab Res.
2006;
38
434
21
Ohmura E, Hosaka D, Yazawa M, Tsuchida A, Tokunaga M, Ishida H, Minagawa S, Matsuda A, Imai Y, Kawazu S, Sato T.
Association of free fatty acids (FFA) and tumor necrosis factor-alpha (TNF-alpha) and insulin-resistant metabolic disorder.
Horm Metab Res.
2007;
39
212-217
22
Schmitz G, Langmann T.
Metabolic learning in the intestine: adaptation to nutrition and luminal factors.
Horm Metab Res.
2006;
38
452-454
23
Ansurudeen I, Kopprasch S, Ehrhart-Bornstein M, Willenberg HS, Krug AW, Funk RH, Bornstein SR.
Vascular-adrenal niche - endothelial cell-mediated sensitization of human adrenocortical cells to angiotensin II.
Horm Metab Res.
2006;
38
476-480
24
Slama G, Elgrably F, Kabir M, Rizkalla SW.
Role of low-glycemic-index foods in improving overall glycemic control in type 1 and type 2 diabetic patients and correcting excessive postprandial hyperglycemia.
Horm Metab Res.
2006;
38
465-468
25
Pistrosch F, Koehler C, Wildbrett J, Hanefeld M.
Relationship between diurnal glucose levels and HbA1c in type 2 diabetes.
Horm Metab Res.
2006;
38
455-459
26
Lamounier-Zepter V, Ehrhart-Bornstein M, Bornstein SR.
Metabolic syndrome and the endocrine stress system.
Horm Metab Res.
2006;
38
437-441
27
Bornstein SR, Schuppenies A, Wong ML, Licinio J.
Approaching the shared biology of obesity and depression: the stress axis as the locus of gene-environment interactions.
Mol Psychiatry.
2006;
11
892-902
28
Reichel A, Schwarz J, Schulze J, Licinio J, Wong ML, Bornstein SR.
Depression and anxiety symptoms in diabetic patients on continuous subcutaneous insulin infusion (CSII).
Mol Psychiatry.
2005;
10
975-976
29
Wenying Y, Zhaojun Y.
Obesity and hypertension as two anthropometric predictors for metabolic syndrome.
Horm Metab Res.
2006;
38
469-470
30
Schwarz PE, Schwarz J, Schuppenies A, Bornstein SR, Schulze J.
Development of a diabetes prevention management program for clinical practice.
Public Health Rep.
2007;
122
258-263
31
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM.
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
N Engl J Med.
2002;
346
393-403
32
Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M.
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.
N Engl J Med.
2001;
344
1343-1350
33
Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M.
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.
Lancet.
2002;
359
2072-2077
34
Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV.
Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study.
Diabetes Care.
1997;
20
537-544
35
Snitker S, Watanabe RM, Ani I, Xiang AH, Marroquin A, Ochoa C, Goico J, Shuldiner AR, Buchanan TA.
Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study.
Diabetes Care.
2004;
27
1365-1368
36
Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L.
XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the preven-tion of type 2 diabetes in obese patients.
Diabetes Care.
2004;
27
155-161
37
Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V.
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Diabetologia.
2006;
49
289-297
38
Schwarz PEH, Schwarz J, Bornstein SR, Schulze J.
Prevention of type 2 diabetes: what challenges do we have to address?.
J. Public Health.
2005;
13
303-308
39
Schwarz PE, Schuppenies A, Gruhl U, Hoffmann R, Bornstein SR, Schulze J, Landgraf R.
Prevention of type 2 diabetes in Germany. Ideas, evidence, implementation.
Med Klin (Munich).
2006;
101
730-736
40
Schwarz P.
Targeted diabetes prevention in high risk groups: pro.
Dtsch Med Wochenschr.
2005;
130
1103
41
Roubideaux Y, Buchwald D, Beals J, Middlebrook D, Manson S, Muneta B, Rith-Najarian S, Shields R, Acton K.
Measuring the quality of diabetes care for older american indians and alaska natives.
Am J Public Health.
2004;
94
60-65
42
Schwarz PE, Bornstein SR, Hanefeld M.
Elevated fasting glucose levels predicts IGT and diabetes also in middle-age subjects.
Diabetes Res Clin Pract.
2007;
77
148-150
43
Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, Hamalainen H, Harkonen P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M, Tuomilehto J.
Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study.
Lancet.
2006;
368
1673-1679
44
Saaristo T, Peltonen M, Lindstrom J, Saarikoski L, Sundvall J, Eriksson JG, Tuomilehto J.
Cross-sectional evaluation of the Finnish Diabetes Risk Score: a tool to identify undetected type 2 diabetes, abnormal glu-cose tolerance and metabolic syndrome.
Diab Vasc Dis Res.
2005;
2
67-72
45
Schwarz PEH, Li J, Wegner H, Bornstein SR, Lindström J, Tuomilehto J.
An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes, response to schulze et al.
Diabetes Care.
2007;
30
e87
46
Schwarz PE, Peltonen M.
Prevention of Type 2 diabetes - Lessons we have Learnt for Implementation.
Horm Metab Res.
2007;
39
636-641
47
Schwarz PE, Govindarajalu S, Towers W, Schwanebeck U, Fischer S, Vasseur F, Bornstein SR, Schulze J.
Haplotypes in the Promoter Region of the ADIPOQ Gene are Associated with Increased Diabetes Risk in a German Caucasian Population.
Horm Metab Res.
2006;
38
447-451
48
Rudofsky
Jr
G, Schrodter A, Voron’ko OE, Schlotterer A, Humpert PM, Tafel J, Nawroth PP, Bierhaus A, Hamann A.
Promoter polymorphisms of UCP1, UCP2, and UCP3 are not associated with diabetic microvascular complications in type 2 diabetes.
Horm Metab Res.
2007;
39
306-309
49
Schwarz PE, Towers GW, Fischer S, Govindarajalu S, Schulze J, Bornstein SR, Hanefeld M, Vasseur F.
Hypoadiponectinemia is associated with progression toward type 2 diabetes and genetic variation in the ADIPOQ gene promoter.
Diabetes Care.
2006;
29
1645-1650
Correspondence
Dr. P.E.H. Schwarz
Division of Endocrinology
Department of Medicine III
Medical Faculty Carl-Gustav-Carus
Technical University Dresden
01307 Dresden
Germany
Phone: +49/351/458 27 15
Fax: +49/351/458 73 19
Email: peter.schwarz@uniklinikum-dresden.de